7月17日，葛兰素史克盘中下跌3.02%，报51.175美元/股，成交额4.04亿美元。
消息面上，公司宣布终止camlipixant在难治性慢性咳嗽适应症的开发。三期临床CALM-1和CALM-2试验结果不一致：50mg剂量在CALM-1中显著降低24小时咳嗽频率，但在CALM-2中未达统计学显著性；25mg剂量则在两项试验中均未达到主要终点。该药物为高选择性P2X3受体拮抗剂，系GSK于2023年斥资20亿美元全额现金收购Bellus Health的核心资产，原本被市场寄予填补难治性慢性咳嗽临床空白的厚望。公司表示有限的疗效是终止开发的主要原因，但肠易激综合征方向的二期临床试验将继续推进。本次核心呼吸管线失败大幅削弱公司呼吸板块中长期增长预期，市场担忧并购投入回报不及预期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.